MedTrace Logo

Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden

NCT01356914 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of the study is to determine whether treatment with BMS-914392 is safe, well tolerated and associated with a reduction of atrial fibrillation burden in patients with paroxysmal atrial fibrillation and permanent pacemaker.

Conditions

Interventions

DRUG

BMS-914392

Tablets, Oral, 10 mg, Every Day (QD), 20 days

DRUG

BMS-914392

Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days

DRUG

BMS-914392

Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days

DRUG

Placebo

Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01356914 on ClinicalTrials.gov